ALK and non-small cell lung carcinoma: The phase III clinical trial AdvanTIG-302 (NCT04746924), sponsored by the pharmaceutical company BeiGene, is a multicentre, international, randomized, and double-blinded study analyzing the combo ociperlimab plus tislelizumab for the first-line treatment of patients with locally advanced, unresectable, or metastatic NSCLC whose tumors exhibit high PD-L1 expression and do not harbor EGFR-sensitizing mutations or ALK translocations.